Tuesday, August 3, 2021 Daily Archives

BioProcess Insider Interview – Marc Hummersone, Astrea Bioseparations

Deprecated: implode(): Passing glue string after array is deprecated. Swap the parameters in /var/www/wp-content/plugins/wistia-wordpress-oembed-plugin/wistia-anti-mangler.php on line 579

BioProcess Insider brings the biotechnology news as it breaks. For the on-demand BPI Theater at the Biotechnology Innovation Organization’s 2021 convention, founding editor Dan Stanton interviewed leading biopharmaceutical executives in early June 2021. Highlighting the rapid proliferation of cell and gene therapies (CGTs), Hummerson described how his company seeks to support downstream processing for emerging therapies. Hummerson reflected that when he joined the biopharmaceutical industry in 2006, developers of monoclonal antibodies (MAbs) expressed great need for innovative purification solutions. The…

CGMP Manufacturing Facility Design and Evolution

Deprecated: implode(): Passing glue string after array is deprecated. Swap the parameters in /var/www/wp-content/plugins/wistia-wordpress-oembed-plugin/wistia-anti-mangler.php on line 579

Presented by: Mike Alston, Jr., director, project engineering; and William Leonardi, PhD, senior project manager, Avid Bioservices These two speakers shared lessons learned in the design and buildout of current good manufacturing practice (CGMP) manufacturing facilities at Avid. Leonardi began with a history of the company’s 28+ years of biologics development and manufacturing and its track record as a successful contract and development manufacturing organization (CDMO). Avid’s main campus comprises a cluster of buildings in Tustin, CA. GMP, process-development, and…

Sanofi bolsters mRNA capabilities with Translate buy

Sanofi will acquire its partner Translate Bio for $38.00 per share, as it looks to drive mRNA technology for therapeutics and vaccines. Under the terms of the deal, Sanofi will acquire Translate for a total equity value of approximately $3.2 billion as the French pharma giant builds on its plans to invest €400 million ($475 million) annually into what it describes as its ‘mRNA Center of Excellence’ to accelerate R&D of next-generation vaccines. In 2018, Sanofi teamed up with Translate…